Bristol-Myers Squibb Company
Selective NR2B antagonists

Abstract:

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. ##STR00001##